1Brilla CG, Pick R, Tan LB, et al. Remodeling of the rat right and left ventricles in experimental hypertension. Circ Res, 1990, 67 : 1355-1364.
2Takeda Y, Yoneda T, Demura M, et al. Cardiac aldosterone production in genetically hypertensive rats. Hypertension, 2000, 36:495-500.
3Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldaetone evaluation study investigators. N Engl J Meal, 1999, 341:709-717.
4Pitt B, Remme W, Zarmad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med, 2003, 348:1309 1321.
5Pitt B, Reichek N, WiUenbreck R, et al. Effects of eplerenone, enalapril and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation, 2003, 108 : 1831-1838.
6Udelson JE, Feldman AM, Greenberg B, et al. Randomized, Double Blind, Multicenter, placebo-controlled study evaluating the effect of aldosterone antagonism with eplerenone on ventricular remodeling in patients with mild-to-moderate heart failure and left ventricular systolic dysfunction. Circ Heart Fail, 2010, 18.
7Young M, Funder J. Mineralocorticoid action and sodium-hydrogen exchange: studies in experimental cardiac fibrosis. Endocrinology, 2003, 144:3848-3851.
8Fujisawa G, Okad, K, Muto S, et al. Na+/H+exchange iaoform l is involved in mineralocorticoid/salt-induced cardiac injury. Hypertension, 2003, 41 : 493-498.
9Ebata S, Muto S , Okada K, et 81. Aldosterone activates Na +/ H + exchange in vascular smooth muscle cells by nongenomic and genomic mechanisms. Kidney Int, 1999, 56: 1400-1412.
10Miyata Y, Muto S, Kusano E, et al. Mechanisms for nongenomic and genomic effects of aldosterone on Na +/H + exchange in vascular smooth muscle cells. Hypertension, 2005, 23:2237-2250.
